Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3357 studies found for:    Open Studies | "Carcinoma"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Drug: MLN0128
2 Recruiting Laparoscopic Versus Open Liver Resection in the Treatment of Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Procedure: Laparoscopic liver resection;   Procedure: Open liver resection
3 Recruiting 18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Device: 18F-FluoroethylCholine PET
4 Recruiting Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Device: The imaging biomarkers determined by MR-PET
5 Recruiting Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Pembrolizumab;   Procedure: Peripheral Blood Sample (optional);   Genetic: Tumor Tissue Collection (optional)
6 Recruiting Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Drug: Sorafenib
7 Recruiting Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Device: liver Perfusion MRI
8 Recruiting SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE
Condition: Carcinoma, Hepatocellular
Intervention: Radiation: SBRT
9 Recruiting A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Conditions: Advanced Adult Hepatocellular Carcinoma;   Advanced Fibrolamellar Carcinoma
Intervention: Drug: ENMD-2076
10 Recruiting Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
Condition: Hepatocellular Carcinoma
Interventions: Drug: CF102;   Drug: Placebo
11 Not yet recruiting A Study of DC-CIK to Treat Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma (HCC)
Intervention: Biological: Dendritic and Cytokine-induced Killer Cells
12 Not yet recruiting Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
Condition: Hepatocellular Carcinoma
Interventions: Genetic: GLYCAR T cells;   Drug: Cytoxan;   Drug: Fludarabine
13 Not yet recruiting Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety
Condition: Adenocystic Carcinoma
Intervention: Drug: Chidamide
14 Recruiting A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Device: CyberKnife
15 Recruiting Neck Dissection Via a Robot-assisted Transaxillary Approach in Patients With Squamous Cell Carcinoma of the Epi-larynx
Condition: Carcinoma, Squamous Cell
Intervention: Procedure: Neck Dissection
16 Recruiting RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma, Adult
Interventions: Drug: Chemotherapy drug;   Drug: Embolic agents;   Procedure: Simultaneously;   Procedure: Sequentially;   Device: Ablation
17 Recruiting Topical Itraconazole in the Treatment of Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Itraconazole
18 Recruiting Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
19 Not yet recruiting Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients
Condition: Neuroendocrine Carcinomas
Intervention: Drug: TLC 388
20 Not yet recruiting Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Donafenib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.